2. Search Result
Search Result
Results for "

mitochondrial fragmentation

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Biochemical Assay Reagents

4

Natural
Products

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-172942
    SP11

    		Mitochondrial Metabolism Reactive Oxygen Species (ROS) Dynamin Cardiovascular Disease Infection Neurological Disease Cancer
    SP11 is a mitochondrial fission protein 1 (Fis1) inhibitor with an IC50 of 9.4 μM. SP11 binds only to activated Fis1 by engaging Cys41. SP11 preserves mitochondrial integrity and function during oxidative stress, inhibits hydrogen peroxide-induced mitochondrial ROS production, mitochondrial fragmentation, and Drp1 mitochondrial translocation. SP11 can be used for the research of parkinson’s disease .
    SP11
  • HY-148009
    Cardiolipin (16:0/18:1/16:0/18:1) sodium

    16:0-18:1 Cardiolipin sodium

    		 Biochemical Assay Reagents Others
    Cardiolipin (16:0/18:1/16:0/18:1) (16:0-18:1 Cardiolipin) sodium is a di-saturated mitochondrial-specific anionic phospholipid sodium salt containing the long-chain fatty acid palmitic acid (HY-N0830) and the monounsaturated fatty acid oleic acid (HY-N1446). Cardiolipin (16:0/18:1/16:0/18:1) sodium undergoes in-source fragmentation via diglyceride (DG)-H2O fragment formation and (DG-H2O) fragment loss pathways. Cardiolipin (16:0/18:1/16:0/18:1) sodium can be used in the synthesis of lipid nanodiscs for application in in situ mass spectrometry .
    Cardiolipin (16:0/18:1/16:0/18:1) sodium
  • HY-112624K
    Dextran T5 (MW 5,000)

    Dextran 5; Dextran D5; Dextran T5(MW 4500-5500)

    		 Apoptosis Autophagy Others
    Dextran T5 (MW 5,000) is a sulfated polysaccharide anti-apoptotic and autophagic agent. Dextran T5 (MW 5,000) has sulfated groups and interacts with cell membranes by mimicking endogenous glycosaminoglycans, inhibiting the mitochondrial apoptotic pathway and delaying DNA fragmentation to exert anti-apoptotic activity. Dextran T5 (MW 5,000) also promotes the conversion of LC3-I to LC3-II and the formation of autophagosomes to activate the autophagic pathway. Dextran T5 (MW 5,000) can prolong the survival cycle of CHO cells and increase the production of recombinant erythropoietin (EPO). The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong drug half-life, increase local concentration and reduce immune clearance activity. The Dextran series of compounds are also natural polysaccharide drug carriers that can be connected to drugs through covalent bonding methods such as ester bonds, amide bonds or click chemistry, or self-assembled to form carriers such as nanoparticles and hydrogels. Dextran is biodegradable and biocompatible, and can achieve targeted delivery and controlled release of drugs. Dextran derivatives can prolong the half-life of drugs, increase local concentrations, and reduce the activity of immune clearance .
    Dextran T5 (MW 5,000)
  • HY-164566
    POSH-IN-2

    		Dynamin Mitochondrial Metabolism Neurological Disease
    POSH-IN-2 (MIDI), a mitochondrial division inhibitor, is a DRP1 inhibitor that potently blocks mitochondrial fragmentation induced by cellular stresses and genetic mitochondrial lesions. POSH-IN-2 covalently interacts with DRP1-C367 to target DRP1 interaction with multiple receptors .
    POSH-IN-2
  • HY-177306
    Opitor-0

    		Dynamin Cancer
    Opitor-0 is a potent and selective inhibitor of mitochondrial dynamin-related protein Optic Atrophy 1 (OPA1) guanosine triphosphatase (GTPase) with an IC50 of 3 μM. Opitor-0 can induce fragmentation of mitochondria and remodeling of cristae, disrupt the stability of OPA1 oligomers, and significantly enhance the release of cytochrome c and induce apoptosis. Opitor-0 has a synergistic antitumor effect with Bcl-2 inhibitors, such as ABT-737 (HY-50907) and Venetoclax (HY-15531). Opitor-0 can be used for the research of malignant tumors that are resistant to Bcl-2 inhibitors, such as triple-negative breast cancer (TNBC) .
    Opitor-0
  • HY-N1306
    Sideroxylin

    		Bacterial Reactive Oxygen Species (ROS) Apoptosis Infection Cancer
    Sideroxylin is a C-methylated flavone isolated from Callistemon lanceolatus and exerts antimicrobial activity against Staphylococcus aureus. Sideroxylin inhibits ovarian cancer cell proliferation and induces apoptosis, causing DNA fragmentation, depolarization of the mitochondrial membrane, the generation of reactive oxygen species (ROS) .
    Sideroxylin
  • HY-N10443
    Mammea A/BA

    		Parasite Apoptosis Autophagy Reactive Oxygen Species (ROS) Infection
    Mammea A/BA has potent activity against Trypanosoma cruzi (T. cruzi). Mammea A/BA induces mitochondrial dysfunction, reactive oxygen species (ROS) production and DNA fragmentation, and increases number of acidic vacuoles. Mammea A/BA can induce apoptosis, autophagy and necrosis. Mammea A/BA can be used for researching chagas disease .
    Mammea A/BA
  • HY-174377
    PeS-9

    		Androgen Receptor p38 MAPK Caspase Cytochrome P450 Calcium Channel Reactive Oxygen Species (ROS) Apoptosis Mitochondrial Metabolism GLUT Cancer

    PeS-9 is an Androgen Receptor (AR) degrader that induces androgen receptor degradation PeS-9 induces mitochondrial and ER stress by promoting cytotoxic ROS production, leading to the release of mitochondrial cytochrome C and AIF. PeS-9 subsequently activates caspases-9 and -3, causing DNA fragmentation and apoptotic cell death. PeS-9 has anticancer activity against prostate cancer and exerts in vivo antitumor and antimetastatic activity with minor side effects. PeS-9 can be used for the study of targeting monotherapy against GLUT-1-overexpressing tumors .
    PeS-9
  • HY-171184
    EAPB0503

    		PARP Bcr-Abl Apoptosis Mitosis Cancer
    EAPB0503 is a quinoline compound with anti-tumor activity, showing strong cytotoxicity against melanoma cells in vitro (IC50=200 nM). EAPB0503 can induce specific cell cycle arrest in mitosis of CML cells and directly activate apoptosis, leading to an increase in the G0 cell population, disruption of mitochondrial membrane potential, PARP cleavage, and DNA fragmentation. EAPB0503 also reduces the levels of BCR-ABL protein .
    EAPB0503
  • HY-178099
    Apoptosis inducer 45

    		Apoptosis Caspase PARP Bcl-2 Family Cancer
    Apoptosis inducer 45 is an apoptosis inducer. Apoptosis inducer 45 is cytotoxically active against the MCF-7 cell line. Apoptosis inducer 45 elicits MCF-7 cell apoptosis via the mitochondrial pathway (increases the Bax/Bcl-2 ratio) by activating cleavage of caspase-9, thereby inducing the fragmentation of DNA repair protein PARP. Apoptosis inducer 45 also can induce caspase-8 cleavage, subsequently initiating cleavage of caspase-3 and its downstream protein PARP to culminate in the extrinsic apoptosis. Apoptosis inducer 45 can be used in the research of breast cancer .
    Apoptosis inducer 45
  • HY-159518
    ROS inducer 4

    		Reactive Oxygen Species (ROS) Mitochondrial Metabolism Apoptosis Cancer
    ROS inducer 4 (compound TE3) is a mitochondrial inhibitor. ROS inducer 4 causes a series of mitochondria-related physiological changes in tumors, such as mitochondrial fragmentation, explosive generation and accumulation of ROS, decreased mitochondrial membrane potential, decreased ATP content, and activation of ROS-mediated apoptotic signaling in mitochondria .
    ROS inducer 4
  • HY-121642
    SL-017

    		Others Others
    SL-017 is a novel photoacoustic sensitizer and a derivative of photofrin B. It can be taken up by cells to the maximum extent within 30 minutes and is mainly localized in mitochondria. After being activated by visible light or ultrasound, SL-017 can significantly increase the production of reactive oxygen species (ROS). Low concentrations of SL-017 can rapidly cause the loss of mitochondrial membrane potential. SL-017 can also cause mitochondrial fragmentation, a process that occurs after the loss of membrane potential. Epoxyeicosatrienoic acids (EETs) can alleviate the loss of mitochondrial membrane potential caused by SL-017, but the antioxidant ascorbic acid has no such effect. These characteristics indicate that SL-017 mainly targets mitochondria and exerts its cytotoxic effect by triggering the collapse of mitochondrial membrane potential, generating ROS, and causing mitochondrial fragmentation. As a novel photoacoustic sensitizer, SL-017 has potential application value in photodynamic therapy and sonodynamic therapy.
    SL-017
  • HY-N8617
    Trijuganone C

    		DNA/RNA Synthesis Caspase PARP Bcl-2 Family Mitochondrial Metabolism Apoptosis Cancer
    Trijuganone C is a tanshinone-type diterpenoid compound. Trijuganone C can be isolated from the roots of Salvia miltiorrhiza Bunge. Trijuganone C induces chromatin condensation, DNA fragmentation, activation of Caspase-3, -8 and -9, as well as cleavage of PARP. Trijuganone C activates Bid and Bax, leading to loss of mitochondrial membrane potential and inducing the release of cytochrome c from mitochondria into the cytosol. Trijuganone C exerts antiproliferative effects through Apoptosis induction mediated by Mitochondrial dysfunction and Caspase activation. Trijuganone C exhibits significant antiproliferative activity against leukemia cells and colon cancer cells .
    Trijuganone C
  • HY-176775
    TPP-IOA

    		Oxidative Phosphorylation Mitochondrial Metabolism Apoptosis Neurological Disease
    TPP-IOA is a cytochrome c peroxidase inhibitor. TPP-IOA inhibits apoptosis by preventing cardiolipin oxidation and cytochrome c release to the cytosol. TPP-IOA disrupts oxidative phosphorylation in isolated mitochondria. TPP-IOA inhibits cell death in SH-SY5Y cells grown in glucose, but not galactose. TPP-IOA causes mitochondrial depolarization and network fragmentation. TPP-lOA mitigates radiation induced death in mice .
    TPP-IOA
  • HY-N3055
    Pinusolide

    		Apoptosis AMPK Platelet-activating Factor Receptor (PAFR) Caspase Neurological Disease Metabolic Disease Cancer
    Pinusolide is an AMPK activator and PAF receptor antagonist. Pinusolide activates AMPK, phosphorylates ACC, enhances IRS-1 tyrosine phosphorylation, boosts glucose uptake, and modulates insulin signaling. Pinusolide inhibits caspase-3/7 activation, intracellular calcium elevation, reactive oxygen species overproduction, lipid peroxidation, and tumor cell proliferation. Pinusolide stabilizes superoxide dismutase activity, reduces apoptotic hallmarks, induces mitochondrial pathway apoptosis, and triggers DNA fragmentation. Pinusolide can be used for the research of type 2 diabetes, neurodegenerative diseases, acute lymphoblastic leukemia, acute myeloid leukemia, and Burkitt lymphoma .
    Pinusolide

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: